|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
|---|---|
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00037050 |
Purpose
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
| Condition | Intervention | Phase |
|---|---|---|
|
Bacterial Infections Gram-Positive Bacterial Infections Bacteremia |
Drug: Antibiotic Drug: Vancomycin Drug: Oxacillin Drug: Dicloxacillin |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections |
| Estimated Enrollment: | 960 |
| Study Start Date: | April 2002 |
| Estimated Study Completion Date: | July 2005 |
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | M12600080, A5951060 |
| Study First Received: | May 14, 2002 |
| Last Updated: | March 20, 2007 |
| ClinicalTrials.gov Identifier: | NCT00037050 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Systemic Inflammatory Response Syndrome Bacterial Infections Anti-Bacterial Agents Sepsis Gram-Positive Bacterial Infections Dicloxacillin |
Oxacillin Vancomycin Bacteremia Linezolid Inflammation |
|
Bacterial Infections Systemic Inflammatory Response Syndrome Anti-Infective Agents Communicable Diseases Dicloxacillin Bacteremia Oxacillin Infection |
Pharmacologic Actions Inflammation Anti-Bacterial Agents Gram-Positive Bacterial Infections Sepsis Pathologic Processes Therapeutic Uses Vancomycin |